Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6606141 | 1.00 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL5853749 | 1.00 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL6323427 | 1.00 | KCNH2 (1.00) | KCNH2 | |
| Hydrochloric Acid SCHEMBL7721167 | 0.99 | KCNH2 (0.99) | KCNH2 | |
| Hydrochloric Acid SCHEMBL7721165 | 0.99 | KCNH2 (0.99) | KCNH2 | |
| Hydrochloric Acid SCHEMBL7721162 | 0.99 | KCNH2 (0.99) | KCNH2 | |
| SCHEMBL7720871 | 0.96 | KCNH2 (0.92) | KCNH2 | |
| SCHEMBL7720868 | 0.96 | KCNH2 (0.92) | KCNH2 | |
| SCHEMBL7720875 | 0.96 | KCNH2 (0.92) | KCNH2 | |
| SCHEMBL6661380 | 0.93 | KCNH2 (0.87) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982334-B2 | powder X-ray diffraction patterns of diastereoisomers; nontoxic bactericide; Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecium or Moraxella catharrhalis | AVENTIS PHARMA S.A. (FR) | 2006-01-03 | — | — | US | claimed |
| US-6939970-B2 | Crystalline form of (3R,4R)-4-[3-(S)-hydroxy-3-(6 methoxyquinolin-4-propyl]-1-[2-2-thienylthio)ethyl] piperidine-3-carboxylic acid | AVENTIS PHARMA S. A. (FR) | 2005-09-06 | — | — | US | claimed |
| US-20040147751-A1 | Crystalline form of (3R,4R)-4-[3-(S)-Hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperindine-3-carboxylic acid | AVENTIS PHARMA S. A. (FR) | 2004-07-29 | — | — | US | claimed |
| US-20040147554-A1 | Crystalline form of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxy-quinolin-4-yl)propyl]-1-[2-2thienylthio)ethyl] piperidine-3-carboxylic acid | AVENTIS PHARMS S.A. (FR) | 2004-07-29 | — | — | US | claimed |
| US-6982334-B2 | powder X-ray diffraction patterns of diastereoisomers; nontoxic bactericide; Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecium or Moraxella catharrhalis | AVENTIS PHARMA S.A. (FR) | 2006-01-03 | — | — | US | disclosed |
| US-6982334-B2 | powder X-ray diffraction patterns of diastereoisomers; nontoxic bactericide; Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecium or Moraxella catharrhalis | AVENTIS PHARMA S.A. (FR) | 2006-01-03 | — | — | US | disclosed |
| US-6982334-B2 | powder X-ray diffraction patterns of diastereoisomers; nontoxic bactericide; Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecium or Moraxella catharrhalis | AVENTIS PHARMA S.A. (FR) | 2006-01-03 | — | — | US | disclosed |
| US-6939970-B2 | Crystalline form of (3R,4R)-4-[3-(S)-hydroxy-3-(6 methoxyquinolin-4-propyl]-1-[2-2-thienylthio)ethyl] piperidine-3-carboxylic acid | AVENTIS PHARMA S. A. (FR) | 2005-09-06 | — | — | US | disclosed |
| US-6939970-B2 | Crystalline form of (3R,4R)-4-[3-(S)-hydroxy-3-(6 methoxyquinolin-4-propyl]-1-[2-2-thienylthio)ethyl] piperidine-3-carboxylic acid | AVENTIS PHARMA S. A. (FR) | 2005-09-06 | — | — | US | disclosed |
| EP-1218370-B1 | QUINOLYL PROPYL PIPERIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | AVENTIS PHARMA SA (FR) | 2004-12-08 | — | — | EP | disclosed |
| US-20040147751-A1 | Crystalline form of (3R,4R)-4-[3-(S)-Hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperindine-3-carboxylic acid | AVENTIS PHARMA S. A. (FR) | 2004-07-29 | — | — | US | disclosed |
| US-20040147751-A1 | Crystalline form of (3R,4R)-4-[3-(S)-Hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperindine-3-carboxylic acid | AVENTIS PHARMA S. A. (FR) | 2004-07-29 | — | — | US | disclosed |
| US-20040147751-A1 | Crystalline form of (3R,4R)-4-[3-(S)-Hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperindine-3-carboxylic acid | AVENTIS PHARMA S. A. (FR) | 2004-07-29 | — | — | US | disclosed |
| US-20040147554-A1 | Crystalline form of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxy-quinolin-4-yl)propyl]-1-[2-2thienylthio)ethyl] piperidine-3-carboxylic acid | AVENTIS PHARMS S.A. (FR) | 2004-07-29 | — | — | US | disclosed |
| US-20040147554-A1 | Crystalline form of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxy-quinolin-4-yl)propyl]-1-[2-2thienylthio)ethyl] piperidine-3-carboxylic acid | AVENTIS PHARMS S.A. (FR) | 2004-07-29 | — | — | US | disclosed |
| WO-2004060886-A1 | (3R, 4R)-4-'3-(S)-HYDROXY-3-(6-MEHTOXYQUINOLIN-4-YL) PROPYLI [-1-'2-(2-THIENYLTHIO) ETHYL ]IPIPERIDINE-3-CARBOXYLIC ACID CRYSTALLINE FORM | AVENTIS PHARMA S.A (FR) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004058748-A1 | CRYSTALLINE FORM OF (3R,4R)-4-[3-(S)-HYDROXY-3-(6-METHOXYQUINOLINE-4-YL)PROPYL]-1-[2-(2-THIENYLTHIO) ETHYL]PIPERIDINE-3-CARBOXYLIC ACID | AVENTIS PHARMA S.A. (FR) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058748-A1 | CRYSTALLINE FORM OF (3R,4R)-4-[3-(S)-HYDROXY-3-(6-METHOXYQUINOLINE-4-YL)PROPYL]-1-[2-(2-THIENYLTHIO) ETHYL]PIPERIDINE-3-CARBOXYLIC ACID | AVENTIS PHARMA S.A. (FR) | 2004-07-15 | — | — | WO | disclosed |
| US-6403610-B1 | ANTIMICROBIAL AGENTS | AVENTIS PHARMA S.A. (FR) | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147554-A1 | Crystalline form of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxy-quinolin-4-yl)propyl]-1-[2-2thienylthio)ethyl] piperidine-3-carboxylic acid | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NOD1, NLRP3 | KCNH2 871/4885 |
| US-20040147751-A1 | Crystalline form of (3R,4R)-4-[3-(S)-Hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperindine-3-carboxylic acid | SFPQ, NOD1, NLRP3 | KCNH2 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.